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Understanding individual variation is fundamental to
personalized medicine. Yet interpreting complex
phenotype data, such as multi-compartment metab-
olomic profiles, in the context of genotype data for
an individual is complicated by interactions within
and between cells and remains an unresolved chal-
lenge. Here, we constructedmulti-omic, data-driven,
personalized whole-cell kinetic models of erythro-
cyte metabolism for 24 healthy individuals based
on fasting-state plasma and erythrocyte metabolo-
mics and whole-genome genotyping. We show that
personalized kinetic rate constants, rather than
metabolite levels, better represent the genotype.
Additionally, changes in erythrocyte dynamics be-
tween individuals occur on timescales of circulation,
suggesting detected differences play a role in phys-
iology. Finally, we use the models to identify individ-
uals at risk for a drug side effect (ribavirin-induced
anemia) and how genetic variation (inosine triphos-
phatase deficiency) may protect against this side
effect. This study demonstrates the feasibility of
personalized kinetic models, and we anticipate their
use will accelerate discoveries in characterizing indi-
vidual metabolic variation.
INTRODUCTION
Biofluid metabolite profiling has been an effective means for
screening and diagnosis of numerous medical diseases (Lan-
pher et al., 2006; Pollitt et al., 1997). It is anticipated that more
in-depth metabolomic profiling will provide even greater insight
into diseases (Holmes et al., 2008; Psychogios et al., 2011).
High-throughput technologies for measuring biomolecules
(Beckonert et al., 2007; Tautenhahn et al., 2012) have aided in
characterizing human variation and driving personalized diag-Cnostics and therapeutics (Wishart et al., 2013). The decreasing
costs of high-throughput data generation are enabling the ability
to shift focus from population-based studies to individuals, and
they even allowed researchers to track a single individual over
a 14-month period (Chen et al., 2012).
Such advances are notable but often do not address interac-
tions occurring within a complexmetabolic network of a cell or its
multi-compartment interactions with the blood stream. Physi-
ology and physiological responses are multi-factorial, so, for
the majority of diseases, a single data type will not be sufficient
for diagnosing, prognosing, and determining appropriate treat-
ment. There is a strong need for a systematic methodology to
integrate complex datasets in a biologically coherent fashion
for understanding measured metabolic and genetic variations
in mechanistic terms.
Genome-scale constraint-based models (Orth et al., 2010) are
a framework for multi-omic data integration that provides a
deeper understanding of metabolic functions than data alone
(Bordbar et al., 2014). Initial studies using these models to inter-
pret individual variation are encouraging, addressing loss-of-
function mutations, such as those found in Mendelian inherited
disorders, or the complete absence of proteins (Agren et al.,
2014; Jamshidi et al., 2011; Jamshidi and Palsson, 2006; Shlomi
et al., 2009), aswell as the integration of gene expression data for
predicting selective cancer drug targets (Yizhak et al., 2014).
However, the majority of human metabolic variation is subtler,
affecting metabolite and enzyme levels as well as enzyme activ-
ity. These changes can affect cellular dynamics, which cannot be
captured by constraint-based models. Whole-cell kinetic
models can be developed from constraint-based models and
can explicitly describe metabolite and enzyme properties (Jam-
shidi and Palsson, 2008a; Stanford et al., 2013). Previous clas-
sical kinetic models have been useful in interpreting individual
variation in a mechanistic fashion (Jamshidi et al., 2002; Saucer-
man et al., 2004), demonstrating the potential to complement or
exceed strictly statistic-based approaches. However, traditional
kinetic models require extensive in vitro parametrization and,
thus, are often impractical for studying large cohorts. A data-
driven approach is needed to study personalized cellular
dynamics.ell Systems 1, 283–292, October 28, 2015 ª2015 Elsevier Inc. 283
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Figure 1. The MASS Approach for Building High-Throughput Personalized Kinetic Models
(A) A baseline human erythrocyte model was tailored to 24 individuals’ plasma and erythrocyte metabolomics. To address inter-individual flux variability, 300
models for each individual were built with candidate flux states from MCMC sampling.
(B) To build the baseline kinetic model, we tailored a global human metabolic network for erythrocyte metabolism using published proteomic data. The network
was integrated with a baseline flux state (from MCMC sampling), Keqs (from literature, when available, and computational estimations), and normal population
metabolite levels (from literature).
(C) The contents and equations of a MASS model are shown.In this study, using plasma and intracellular erythrocytemetab-
olomics, we constructed a collection of personalized whole-cell
kinetic models of erythrocyte metabolism for 24 healthy individ-
uals. The method is a scalable means to integrate individual
metabolitemeasurementswith the underlyingmetabolic network
to determine enzyme activity, providing a more direct means to
compare the genotype with protein function. Analysis of the
models indicates that enzymatic kinetic parameter variation re-
flects genetic variation. Further, a functional kinetic model was
constructed, enabling simulation of perturbations for direct phys-
iological interpretation of the consequences of detected meta-
bolic variation in response to drug exposure.
RESULTS
Network-Based Kinetic Description of Omic Data
Traditionally, kinetic models of biochemical reaction networks
are constructed through a biophysical approach using rate laws
that require in-vitro-derived kinetic parameters (such as Michae-
lis constant, Km; turnover number, kcat; and enzyme concentra-
tion, E0). The difficulty in obtaining kinetic parameters and their
appropriateness for in vivo situations (Teusink et al., 2000) limits
scaling of traditional kineticmodels to large networks, let alone to
a large number of individuals. In recent years, there have been
numerous approaches for building kinetic models for metabolic,
signaling, and gene regulatory networks (Chakrabarti et al., 2013;
Danino et al., 2010; Khodayari et al., 2014; O’Dea et al., 2007;
Stanford et al., 2013). In particular, one approach applies the
law of mass action, which is a fundamental principle in chemistry
and ultimately is the basis and derivation of mechanistic reaction
descriptions. In this study, we applied the Mass Action Stoichio-
metric Simulation (MASS) approach (Jamshidi and Palsson,284 Cell Systems 1, 283–292, October 28, 2015 ª2015 Elsevier Inc.2010), which allows for flexibility in incorporating mechanisms
in varying degrees of detail, to construct personalizedmodels us-
ing metabolomic profiles (Figure 1C).
Briefly, a MASS model is comprised of the network topology,
derived from a metabolic network reconstruction (Feist et al.,
2009; Oberhardt et al., 2009), and high-throughput data repre-
senting the steady state of the network (Figure 1C). Enzyme
kinetics of the metabolic reactions are approximated by a
phenomenological kinetic constant, the pseudo-elementary
rate constant (PERC). The PERC represents a combination of
traditional kinetic parameters and is consistent with all condi-
tion-specific omic data used. A mathematical comparison of
MASS and rate law kinetic models is presented in the Supple-
mental Experimental Procedures, including simulations showing
that individual variability is the overriding factor of dynamic sim-
ulations and not the choice of modeling approach. Thus, MASS
models are a practical approximation of network dynamics
based on an observable homeostatic state. Workflows, advan-
tages, disadvantages, and examples of MASS models have
been discussed previously (Jamshidi and Palsson, 2008a; Jam-
shidi and Palsson, 2010; Palsson, 2011) and demonstrated for
cellular models of metabolism. This approach has not yet been
implemented for the simultaneous construction of a library of in-
dividual-specific personalized models using in vivo omic data.
Workflow for Personalized Kinetic Model Construction
The workflow to build personalized erythrocyte kinetic models is
shown in Figures 1A and 1B.We first built a baselinemodel using
the average metabolite concentrations of the human plasma and
erythrocyte (Figure 1B). A metabolic network reconstruction of
the human erythrocyte (iAB-RBC-283, Bordbar et al., 2011)
was derived from the global human metabolic network (Duarte
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Figure 2. Personalized MASS Models Integrate Omic Data to Obtain
System-Level Understanding of Individual Variation
Two individuals (12 and 17) with differing simulated responses to a redox load
are highlighted with confidence intervals (mean ± SD).
(A) Violin plots of significantly different erythrocyte and plasma metabolite
concentrations accounted for in the model (p < 0.05, Bonferroni corrected,
ANOVA). 39 of the 69 erythrocyte and 39 of the 44 plasma metabolites were
significantly different between at least two individuals, though not necessarily
individuals 12 and 17. Black lines on the violin plots represent the 25th, 50th,
and 75th quantiles.
(B) Metabolite levels are integrated to obtain network kinetic parameters. Violin
plots of significantly different PERCs of intracellular reactions are presented.
54 PERCs in the model were significantly different between at least two in-
dividuals.
(C) An illustrative example of how personalized kinetic models can be simu-
lated to assess systemic differences to perturbations. 25 metabolites and
Cet al., 2007) with the compilation and integration of multiple pro-
teomic datasets obtained from the human erythrocyte (Fig-
ure 1B). The iAB-RBC-283 was then tailored to the scope of
the metabolomic data obtained in this study (Data S1). Average
metabolic concentrations (x) and equilibrium constants (Keq)
were determined from experimental literature. Equilibrium con-
stants not available in the literature were determined through
computational methods (Noor et al., 2012). Reaction fluxes (v)
were determined by Markov chain Monte Carlo (MCMC) sam-
pling (Bordbar et al., 2010; Schellenberger et al., 2011) of the
constraint-based model, where the lower and upper bounds of
exchange fluxes were parameterized by available experimental
data (Data S1). After the various data (v, x, and Keq) were inte-
grated, PERCs (kPERC) could be calculated for all reactions by
solving the equation for the one missing value (Figure 1C). The
flux state was estimated based on available physiological data
through constraint-based modeling and was independent of
the PERC estimates, avoiding potential concerns of overly con-
servative estimates from mass action constraints (Chakrabarti
et al., 2013). The final model and its characteristics are presented
in Figure S1.
Next we measured fasting-state plasma and erythrocyte me-
tabolites for 24 healthy individuals (Figure 1A). Further, measure-
ments were made at four different time points in four individuals
over a 6-week period, allowing us to compare the same individ-
ual across multiple measurements to serve as controls. Overall,
we measured 44 plasma and 69 intracellular erythrocyte metab-
olites, with 76 of the 113 metabolites being present in the MASS
model. We first assessed whether the plasma and intracellular
measurements were redundant. For example, is measuring just
the plasma concentration of a particular metabolite enough to
know the concentration of the intracellular erythrocyte metabo-
lite? We confirmed that the plasma and intracellular metabolite
measurements were not redundant, and measuring intracellular
levels is important for assessing the metabolic state of even a
blood cell. Of the 39 metabolites that were measured in both
the plasma and the erythrocyte, only five (lactic acid, hypoxan-
thine, L-threonine, L-tryptophan, and uridine) were correlated
between the two compartments (R2 > 0.5, p < 0.05, Pearson
correlation).
We constructed a personalized kinetic model for each individ-
ual by substituting the average of the measured metabolite con-
centrations of the individual under consideration for the baseline
levels and calculating a personalized set of PERCs by re-solving
all the equations. For the baseline model, a single flux reaction
state was used. However, individuals might have different base-
line reaction flux states. To address inter-individual flux vari-
ability, we utilized an ensemble approach (Tan and Liao, 2012)
where 300 candidate flux distributions from theMCMC sampling
were used to build 300 models for each individual. Introducing
uncertainty into the reaction flux states mitigated the lack of
direct flux measurements and allowed us to determine signifi-
cantly different distributions of PERCs between ensembles of ki-
netic models for individuals, regardless of flux state (Figure 2B).36 reaction fluxes had significantly different responses between individuals
when the initial NADPH/NADP ratio was perturbed. For example, fructose 1,6-
bisphosphate levels responded quite differently between individuals. See the
Supplemental Experimental Procedures and Figure S4 for simulation details.
ell Systems 1, 283–292, October 28, 2015 ª2015 Elsevier Inc. 285
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Figure 3. Personalized Kinetic Models Can Be Used for Genomic
Discoveries
(A) Significantly different PERCs between individuals are enriched with allelic
differences in the region of the associated genes (left). Removing spurious
PERCs determined from controls increased levels of enrichment (filtered
PERCs). Significantly different metabolite levels are often depleted with allelic
differences in the gene regions whose associated reactions are connected to
the metabolite. Allelic differences also are enriched with significantly different
PERCs (right) and are significantly depleted with significantly different me-
tabolites that are directly linked to reactions associated with the genes.
Comparing metabolite differences to only the most representative reaction
(filteredmetabolite concentrations) connected to that metabolite did artificially
boost results, as expected. However, the results were still not as represen-
tative of the genotypes as those found with the PERCs (*significantly enriched,
ysignificantly depleted; p < 0.05, binomial distribution).
(B) Accuracy of genotype variations as predictors of significantly different
PERCs was significantly correlated (Pearson correlation) with the minor allele
frequency of the SNPs.Further, we assessed the robustness of PERC calculations in
terms of technical variability in metabolomic measurements
(Supplemental Experimental Procedures; Figure S2).
Model Parameters Are Associated with the Genotype
The PERC is a bulk approximation of traditional enzymatic pa-
rameters (Km, kcat, and E0) (Figure 1C). Individual Km and kcat
depend on the protein sequence and the protein-coding exon
DNA sequence. Variation in E0 depends on other non-coding
sequence variations (i.e., variants in promoters, enhancers, syn-
onymous mutations in exons, and splice junctions). Thus, calcu-
lated PERCs also should depend on genetic variants. To assess
this dependence, we focused on genetic variants occurring in
the gene region of the metabolic genes (exon, intron, and pro-
moter regions) in the constructed erythrocyte kinetic model,
thus ignoring variants outside the gene region that may poten-286 Cell Systems 1, 283–292, October 28, 2015 ª2015 Elsevier Inc.tially affect E0. The variants in the chosen region have a higher
chance of being functionally relevant to enzyme kinetic
differences.
To test the biological relevance of PERCs, we determined if
ensembles of PERCs that were significantly different (Experi-
mental Procedures for statistical test) between two individuals
were enriched in allelic differences in the associated gene region
as compared to the underlying allelic variation in those regions
among all individuals (Figure 3A, left). For all genetic variant types
(non-coding, synonymous exon, non-synonymous exon), we
found statistical enrichment (p < 0.05, binomial distribution), sug-
gesting the PERC, in part, depends on the genotype. Further, we
filtered out reactions whose PERCs had high intra-individual dif-
ferences longitudinally within the same individual (Supplemental
Experimental Procedures). The filtering further increased enrich-
ment levels. We next determined whether differences in alleles
between individuals were enriched in ensembles of PERCs that
were significantly different (Figure 3A, right). This test is more
stringent as most genetic variants are not functional. Enrichment
levels were much lower, while non-synonymous and non-coding
genes were not significantly enriched with PERC differences.
Filtering the same reactions with high intra-individual differences
determined from the longitudinal controls from this analysis, all
variant types were statistically enriched.
We then compared significantly different intracellular erythro-
cyte metabolite levels (p < 0.05, ANOVA, Bonferroni corrected)
with genetic variants in gene regions associated with metabolic
reactions producing or consuming the metabolite. Notably,
significantly different metabolite levels were not enriched in dif-
ferences of alleles (p > 0.05, binomial distribution) (Figure 3A,
left), and differences in alleles also were not enriched in signifi-
cantly different metabolite levels (Figure 3A, right). This is most
likely because there is not a 1:1 relationship betweenmetabolites
and reactions. To account for this discrepancy, we separated the
enrichment results into the single reactions associated with the
significantly different metabolite. Next we chose the reaction
that had the best enrichment with the associated metabolite to
create a 1:1 relationship that represents the best-case scenario.
Still, themetabolite differences were not as significantly enriched
in differences of alleles as the ensemble of PERCs (Figure 3A,
left), and allelic differences in selected genes were not signifi-
cantly enriched in differences of metabolite concentration (Fig-
ure 3A, right). This result may be attributable to the following:
(1) metabolite levels and enzyme activity are indirectly linked,
as metabolite levels can vary in a systemwhile the enzyme activ-
ity or concentration stays constant; and (2) cellular systems often
modulate enzyme levels and activity to maintain metabolite
levels.
To further characterize the relationship of PERCs and genetic
variants, we found a significant correlation between the accu-
racy of predicting differences in ensembles of PERCs with the
minor allele frequency (MAF, based on the 1000 Genomes Proj-
ect) of the variant (Figure 3B). This result is consistent with the
notion that functional variants are more likely to be rare (Cargill
et al., 1999).
Temporal Decomposition
In addition to statistical analyses, personalized kinetic models
can be analyzed for mechanistic-based physiological insights
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Figure 4. Temporal Decomposition of the Models Elucidated Personalized Systemic Variations at Specific Timescales
(A) The majority of differences in timescales between different individuals occurred on the order of seconds. This variability in dynamics coincides with the
physiological timescales of blood circulation (1 min).
(B) Metabolic reactions were aggregated based on the timescales of their coordinated activity. The first two timescales are shown. For example, aldolase (FBA)
and triosephosphate isomerase (TPI) are fast reactions, operating near equilibrium, and coordinated within the first timescale. These two reactions then coor-
dinate with the rest of lower glycolysis in the second timescale. Many of the important metabolic pathways for erythrocyte function aggregate on this time
scale (seconds).that are not possible with genome-wide association studies.
Specifically, we analyzed the individual variability in network dy-
namic responses by assessing the properties of the personalized
Jacobian matrices (Palsson et al., 1987). The Jacobian matrix
describes network dynamics around a particular homeostatic
reference state (Heinrich et al., 1977; Jamshidi and Palsson,
2008b; Kauffman et al., 2002). Decomposing the Jacobian
matrix yields the independent dynamic drivers, or modes, of
the network, as well as the time constants under which such
drivers operate (Jamshidi and Palsson, 2009; Experimental
Procedures).
To assess variations in the dynamics across the entire
network, we determined which time constants were signifi-
cantly different between the ensemble models of individuals
(p < 0.05, empirical test). Interestingly, almost all pair-wise dif-
ferences in the time constants occurred between response
times of 1 s and 1 min (Figure 4A), which coincide with the
average capillary transit time (1 s) and average erythrocyte
circulation time (1 min), suggesting that personalized meta-
bolic functions may affect the oxygenation and deoxygenation
processes. The median effect size of time constant differences
was 14.5%, with effect sizes as large as 150%. Repeating the
temporal decomposition analysis with the longitudinal controls,
the results did not have the same specific difference as seen
between individuals, suggesting the results are not an artifactCof the approach (Supplemental Experimental Procedures;
Figure S3).
Next we identified the dominant dynamic features of modes
operating on different timescales (millisecond, second, minute,
hour, and day) to ascertain which metabolic fluxes underlie the
individual variation of the time constants. A previously published
method (Jamshidi and Palsson, 2008b) was applied to determine
when individual fluxes coordinate their activities on the separate
timescales based on themodes. Reaction flux aggregation of the
first two timescales are illustrated in Figure 4B. The first time-
scale (millisecond) is the coordination of very fast reactions
near equilibrium, such as isomerases (phosphoglucose isom-
erase, triosephosphate isomerase, and ribose-5-phosphate
isomerase). The second timescale (second), where most indi-
vidual variation was detected, is characterized by the coordina-
tion of fluxes into parts of key erythrocyte pathways, including
lower glycolysis, the oxidative pentose phosphate pathway,
and glutathione recycling.
Dynamic Simulations for Understanding Ribavirin
Susceptibility
Personalized kinetic models can be used to assess the systemic
responses to perturbations through dynamic simulations (Fig-
ure 5A). We used simulations to study individual responses to
ribavirin (RBV), an anti-viral drug used for the hepatitis C virus.ell Systems 1, 283–292, October 28, 2015 ª2015 Elsevier Inc. 287
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Figure 5. Dynamic Simulations of the Person-
alized Models Generated Novel Predictions
about Susceptibility to Ribavirin-Induced
Hemolytic Anemia
(A) Workflow for personalized drug exposure, iden-
tification of susceptible models, and predictors of
susceptibility are shown.
(B) The ribavirin (RBV) metabolism pathway was
added to each model in order to simulate the RBV
side effect mechanism.
(C) The ensemble models were iteratively simulated
at increasing doses of RBV to determine the plasma
concentration at which the models of an individual
could no longer return to a homeostatic state.
(D) A robust classification tree was constructed that
predisposes whether or not models return to a
steady state. High PERCs for phosphoglycerate ki-
nase (PGK) and adenine transport were identified as
factors of susceptibility.
(E) The ATP/ADP ratio in erythrocytes is correlated
(p = 0.0306, adjusted slope of regression model b =
0.28305, log2 transformed) with the highest
associated variant (rs6051702) of ITPA protection of
RBV-induced hemolytic anemia.A common side effect of RBV is dose-dependent non-immune-
mediated hemolytic anemia (Russmann et al., 2006). The mech-
anism generally accepted for this side effect is that RBV is phos-
phorylated in the erythrocyte, but cannot be dephosphorylated
(Figure 5B). Lack of dephosphorylation causes the accumulation
of >1 mM RBV and its phosphorylated forms (RBV monophos-
phate, RBV diphosphate, and RBV triphosphate) in erythrocytes
(Homma et al., 2004), sequestering >2mM inorganic phosphate.
Curiously, individuals with inosine triphosphatase (ITPA) defi-
ciency, the inability to hydrolase inosine triphosphate to inosine
monophosphate, are protected from this side effect (Fellay et al.,
2010). ITPA deficiency is clinically benign but is marked with a
buildup of inosine triphosphate in erythrocytes (van Waeg
et al., 1988).
RBV phosphorylation kinetic expressions were added to the
models (Supplemental Experimental Procedures). Dynamic sim-
ulations indicated significant decreases in ATP levels and flux
through the sodium-potassium ATP pump, while there were no
significant changes in glutathione levels. These simulated dy-
namic changes were qualitatively concordant with known
changes found in RBV stimulation in vitro (De Franceschi et al.,
2000). Using dynamic simulations, we identified the plasma
RBV concentrations (up to three times the typical plasma RBV
concentration; Brochot et al., 2010), of which each model was
unable to return to a steady state due to drug exposure (Fig-
ure 5C). Most individuals (22 of 24) were non-responders, as288 Cell Systems 1, 283–292, October 28, 2015 ª2015 Elsevier Inc.the ensemble models for those individuals
tolerated RBV. However, for two of the 24
individuals examined, a large proportion
of their ensemble models were unable to
return to a homeostatic state. The simu-
lated side effect incidence rate (2/24,
8.3%) is concordant with the percentage
of RBV patients (n = 1,184) during Phase
III clinical trials (Devine et al., 2001) thathad RBV dosage reduced (7.4%), discontinued (0.3%), or that
received transfusions (0.1%). Further, eight individuals were het-
erozygous and one individual was homozygous for the variant
(rs6051702; Fellay et al., 2010) highest associated with ITPA pro-
tection against RBV-induced hemolytic anemia. All nine of these
individuals were in the non-responder group.
To determine if there was an underlying predisposition in
models that were susceptible to RBV-induced hemolytic ane-
mia, we used classification trees with the ensembles of PERCs
as predictors to classify non-responders versus responders (Fig-
ure 5D). The classifier indicated that high PERCs for phospho-
glycerate kinase (PGK, the first ATP-generating reaction in
glycolysis) and adenine transport are a potential reason for
RBV-induced hemolytic anemia. Previous clinical studies have
identified individuals with hemolytic anemia that had high glyco-
lytic rates and high adenine catabolism (Mills et al., 1968). A high
glycolytic rate and elevated adenine catabolism enable quicker
access of RBV to the ATP pool, thus increasing the RBV phos-
phorylation rate. Further, we modified the metabolite concentra-
tions of the susceptible models of individuals 2 and 13 to lower
the PERCs for PGK and adenine transport and were able to
maintain model homeostasis with normal dosages of RBV (Sup-
plemental Experimental Procedures; Figure S5). Thus, predispo-
sition to RBV-induced hemolytic anemia may be due to an
inability to adapt to high rates of RBV phosphorylation in certain
individuals.
We next determined if protection by ITPA deficiency is related
to the identified classifiers. One of the predisposition factors, the
PERC of PGK (and its associated high glycolytic rate), is depen-
dent on a high ATP/ADP ratio. ITPA deficiency, which leads to a
buildup of ITP in erythrocytes, is in effect sequestering phos-
phate from the total phosphate pool. Changing the phosphate
pool has been shown to affect the ATP/ADP ratio (Minakami
and Yoshikawa, 1966). We found that the ATP/ADP ratio was
significantly associated (p = 0.0306) with rs6051702 (Figure 5C).
Thus, lowered ATP/ADP ratio due to a smaller phosphate pool
may play a role in ITPA deficiency protection from RBV-induced
hemolytic anemia.
DISCUSSION
We developed personalized whole-cell kinetic models of eryth-
rocyte metabolism for 24 healthy individuals using a scalable,
metabolomic-driven workflow. The metabolic network structure
provides the non-linear relationships between metabolites and
enzymes in the form of reaction rate laws. Thus, personal metab-
olite measurements can be interpreted mechanistically to
deduce changes of functional importance, such as enzyme ac-
tivities and cellular dynamics. The approach can be imple-
mented for any cell type for which metabolomic data can be pro-
cured. To our knowledge, a unique feature of this work is that it
represents a bottom-up mechanistic approach to bridge the
variation in dynamic responses of human cellular metabolism
with the underlying genotype, utilizing high-throughput data. Im-
plementation of the MASS approach for building kinetic models
results in predictive models that have implications for acceler-
ating discoveries in understanding human metabolic variation.
Our analysis shows that PERCs, an approximation for enzyme
activity and abundance, are more associated with allelic variants
than metabolite concentrations. PERCs also have larger effect
sizes, making them more sensitive for detecting subtleties in hu-
man metabolic variation than metabolite quantitative trait loci
(Suhre and Gieger, 2012; Suhre et al., 2011). Owing to our sam-
ple size, we only globally studied whether changes in variants
within a gene region of an enzyme were enriched with changes
in the value of the enzyme’s PERC. We anticipate that scale-
up to sample sizes more typical of genome-wide association
studies will provide sufficient statistical power to allow PERCs
to be associated with genetic loci, leading to discoveries in
both how coding variants affect enzyme kinetic properties and
how non-coding variants across the genome affect enzyme
abundance.
Model-driven analysis led us to propose a mechanism for
predisposition to RBV-induced hemolytic anemia. The mecha-
nism is consistent with the well-known protective properties
of ITPA deficiency. An alternative mechanism has been pro-
posed (Hitomi et al., 2011) but with notable shortcomings (Sup-
plemental Experimental Procedures). Follow-up of our mecha-
nism with larger populations is warranted to determine if the
ATP/ADP ratio is in fact a major determinant of susceptibility.
Interestingly, a recent study (Zhao et al., 2013) analyzed the
FDA Adverse Event Reporting System and identified drug com-
binations (Drug A + Drug B) that had lower side effect rates
than Drug A alone. Of the detected 19,000 combinations, two
were related to RBV + Drug B (either ketoprofen or predniso-Clone), which lowered the rate of occurrence of hemolytic ane-
mia as compared to RBV alone. Ketoprofen is a known weak
inhibitor of bacterial glycolytic metabolism (Belli et al., 1995),
concordant with our proposed mechanism. Our results high-
light the utility of kinetic models for pharmacodynamics.
Although the hypothesis can be tested with metabolomic
data, the insight and generation of the hypothesis required
the integration of metabolomic and genotyping data with ki-
netic modeling.
In contrast to parameter-fitting-based approaches, we apply
conservation principles and thermodynamic constraints to the
biochemical network and calculate parameters (PERCs) based
on the resulting feasible points within the flux solution space.
Our findings demonstrate the feasibility and utility of these
models for studying inter-individual variations in physiological
dynamics and drug responses. We anticipate that mechanisti-
cally driven studies that incorporate multiple types of omic
data will become effective means to understanding human vari-
ation and its implications.
EXPERIMENTAL PROCEDURES
Study Sample
University of California, San Diego (UCSD) institutional review board approval
was obtained (Project 111100X) permitting the acquisition and subsequent
analysis of blood from healthy volunteers via peripheral venipuncture. The
24 individuals (16 male, 8 female) who identified themselves as healthy,
without any known chronicmedical conditions, providedwritten informed con-
sent and provided venous blood samples for plasma and erythrocyte metab-
olite profiling as well as SNP genotyping in a morning fasted state (a minimum
of 8 hr). Four of the individuals (individuals 1–4) were sampled for metabolite
profiling four times across 6 weeks as longitudinal controls (weeks 0, 1, 4,
and 6). Their final time point was used in the comparisons against the other
20 individuals.
Sample Preparation
Two vials of blood (8 ml) were drawn from each individual. The first vial
(included in PAXgene blood DNA kit, QIAGEN) subsequently was used for
DNA extraction and SNP genotyping. The Illumina Infinium HumanOmniEx-
pressExome BeadChip was used for SNP genotyping. The UCSD IGM Geno-
mics Center (http://igm.ucsd.edu/core-services/) completed analyses and
made SNP calls. The second vial, containing heparin anticoagulant, was
immediately placed on ice. The vial was split for plasma and intracellular eryth-
rocyte metabolite extraction. Erythrocyte samples were centrifuged (1,000 3
g, 2 min, 4C). Then, 25 ml packed red cells were aliquoted with 25 ml internal
standards (next section) and 450 ml 80C methanol (80%). Tubes were
immersed in liquid nitrogen until frozen to lyse cells. After thawing in a water
bath at room temperature, tubes were centrifuged (15,800 3 g, 15 min,
4C). Supernatant was retained for metabolite profiling and stored at 80C.
Concurrently, plasma samples were centrifuged (3,000 3 g, 20 min, 4C).
Then, 100 ml plasma was aliquoted with 35 ml internal standards and 365 ml
80C methanol (80%). Tubes were centrifuged (15,800 3 g, 15 min, 4C).
The supernatant was retained for metabolite profiling and stored at 80C.
All samples were lyophilized and reconstituted in water and ran at the nom-
inal concentration and at a 10-fold dilution to account for the large concentra-
tion range of intracellular metabolites. Metabolite samples were prepared in
triplicate. Across all samples, 2.8% and 4.0% of the erythrocyte and plasma
metabolomes, respectively, were not detected. These values were imputed
using theweighted average of the five nearest neighbors (Tong, 2008). Theme-
tabolomic data are presented in Data S1. Some metabolites cannot be differ-
entiated experimentally by global mass spectrometry (e.g., 2pg and 3pg) and
aremeasured in pools. To not introduce additional variation in the personalized
models, the ratios of the pooled metabolites were kept constant in the person-
alized models as the baseline model, just the total size of the pool was varied
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Metabolite Profiling: Standards, Instrumentation, Acquisition, and
Quantification
Standards were purchased from Sigma-Aldrich or Santa Cruz Biotechnology.
Liquid chromatography-mass spectrometry (LC-MS) reagents were pur-
chased from Honeywell Burdick & Jackson. Metabolically labeled internal
standards were synthesized as described previously (McCloskey et al.,
2014). Calibrator standards were generated from stock solutions freshly pre-
pared or kept in 80C for no longer than 3 days. Calibrator standards were
combined into mixtures and aliquoted, lyophilized, and stored at 80C. Ali-
quots were reconstituted in water and serially diluted to generate a calibration
curve that spanned the lower and upper limits of detection for each compound.
An XSELECT HSS XP 150 mm 3 2.1 mm 3 2.5 mm (Waters Corporation)
with a UFLC XR HPLC (Shimadzu Scientific Instruments) was used for chro-
matographic separation. Mobile phase A was composed of 10 mM tributyl-
amine (TBA), 10 mM acetic acid (pH 6.86), 5% methanol, and 2% 2-propanol;
mobile phase B was 2-propanol. Oven temperature was 40C. The chromato-
graphic conditions were as follows: 0, 0, 0.4; 5, 0, 0.4; 9, 2, 0.4; 9.5, 6, 0.4; 11.5,
6, 0.4; 12, 11, 0.4; 13.5, 11, 0.4; 15.5, 28, 0.4; 16.5, 53, 0.15; 22.5, 53, 0.15; 23,
0, 0.15; 27, 0, 0.4; and 33, 0, 0.4; (total time [min], eluent B [vol %], flow rate
[ml/min]). The autosampler temperature was 10C and the injection volume
was 10 ml with full loop injection. An AB SCIEX Qtrap 5500 mass spectrometer
(AB SCIEX) was operated in negative mode. Electrospray ionization parame-
ters were optimized for 0.4 ml/min flow rate and were as follows: electrospray
voltage of 4,500 V, temperature of 500C, curtain gas of 40, CAD gas of 12,
and gases 1 and 2 of 50 and 50 psi, respectively. Analyzer parameters were
optimized for each compound using manual tuning. The instrument was
mass calibrated with a mixture of polypropylene glycol (PPG) standards.
Samples were acquired using the scheduled multiple reaction monitoring
(MRM) pro algorithm in Analyst 1.6.2. The acquisition method consisted of
an MRM survey scan coupled to an information-dependent acquisition (IDA)
consisting of an enhanced product ion (EPI) scan for compound identity confir-
mation. Samples were quantified using IDMS39, 40 with metabolically labeled
internal standards and processed using Multiquant 2.1.1. Linear regressions
for compound quantitation were based on peak height ratios and the logarithm
of the concentration of calibrator concentrations from a minimum of four
consecutive concentration ranges that showed minimal bias. A peak height
greater than 1e3 ion counts and a signal-to-noise ratio greater than 20 were
used to define the lower limit of quantitation (LLOQ). Quality controls and
carryover checks were included with each batch. Due to the number of biolog-
ical isomers, the integration of each compound was checked manually.
Constraint-Based Model Construction and Flux Calculations
The human erythrocyte metabolic model was updated using COBRA Toolbox
v2 (Schellenberger et al., 2011) for MATLAB (MathWorks). Model changes
included removing pathways whose majority of metabolites were not
measured and adding reactions based on the additional scope from metabo-
lomic measurements and a recently published proteomic dataset (D’Alessan-
dro et al., 2010). Data S1 details specific changes to the model. Literature
sources (Data S1) were used to set transport flux rates into and out of the
model as well as flux rates of NADH and ATP usage, catalase activity, and
flux ratio splits. Lower and upper bounds for these fluxes were set as the
mean ± SD, where available. Otherwise, flux bounds were set as 75%–
125% of the mean. MCMC sampling (Bordbar et al., 2010; Schellenberger
et al., 2011) was used to determine candidate flux states or sample points;
5,000 sample points were computed and the mean was used as the initial
flux state used to build the baseline model. Of the 5,000, 300 sample points
were randomly chosen to build the ensemble models (Data S1).
Kinetic Model Construction
Kinetic model construction, temporal decomposition, and dynamic simula-
tions were completed with the MASS Toolbox (http://opencobra.github.io/
MASS-Toolbox/) for Mathematica (Wolfram). The MASS modeling approach
and the workflow for building the models have been previously documented
(Jamshidi and Palsson, 2008a; Jamshidi and Palsson, 2010). Initial metabolite
concentrations were set based on literature sources. Plasma concentrations
were assumed to be constant. Concentrations for some metabolites were
not available and were set based on MCMC concentration sampling of ther-
modynamically feasible ranges (Equation 1), where S is the stoichiometric ma-290 Cell Systems 1, 283–292, October 28, 2015 ª2015 Elsevier Inc.trix. The known concentrations were fixed and the remaining concentrations
were calculated. The highest probability concentrations were chosen.
ST, logðxÞ% logðKeqÞif v>0
ST, logðxÞR logðKeqÞif v<0
lb= ub= xknown
(Equation 1)
Equilibrium constants were set based on experimental measurements, where
available, or computational methods (Noor et al., 2012; http://equilibrator.
weizmann.ac.il). Equilibrium constants for transport reactions were set based
on a previous method (Jol et al., 2010). Literature sources for metabolite con-
centrations and equilibrium constants are provided in Data S1. Model stability
was assessed by calculating the Jacobian matrix and checking that eigen-
values were negative or zero within a tolerance of 1010. To achieve linear
stability of the baseline model, the computationally determined equilibrium
constants were varied up to three orders of magnitude and the eigenvalues
of the Jacobianmatrix were re-calculated to determine theminimal adjustment
needed for a stable kinetic model.
The internal standards were used to relatively quantify the plasma and eryth-
rocyte concentrations, and the mean concentration of a metabolite across all
samples was assumed to be the baseline concentration. Measured plasma
and erythrocyte concentrations were minimally adjusted using a quadratic
programming (QP) problem to ensure thermodynamic consistency (Equa-
tion 2). G is the mass action ratio; x0 and G0 are the baseline model concentra-
tions and mass action ratio; ε was set to 10% of the difference of G and Keq.
This ensures that the calculated PERC in later steps is not infinity or negative
infinity.
minðlogðx=x0ÞÞ2 + ðlogðG=G0ÞÞ2
ST, logðxÞ% logðKeqÞ  ε if v>0
ST, logðxÞR logðKeqÞ+ ε if v<0
logð0:5Þ% logðx=x0Þ% logð1:5Þ
(Equation 2)
After integration of personal metabolite data, the measured metabolite con-
centrations were varied up to an order of magnitude and the eigenvalues of
the Jacobian were re-calculatd to determine the minimal adjustment needed
for a stable kinetic model. Once stabilized, 300 ensemble models were built
for each individual model and the baseline model using MCMC sample points.
Themodels were filtered based on their ability to simulate to a steady state due
to a perturbation by decreasing the ATP concentration by 5% and increasing
the ADP concentration by 5%. The number of stable models varied for each
individual from 62 to 287 models, with 48 flux states having a stable kinetic
model for all individuals and the baseline. The 48 models for each individual
were utilized in the study.
The baseline kinetic models built by the MASS and enzymatic rate law ap-
proaches are available in Data S2, Data S3, and BioModels (http://www.ebi.
ac.uk/biomodels-main/). The construction of the enzymatic rate law model is
presented in the Supplemental Experimental Procedures and Data S1.
Statistical Analyses for PERC Comparison with Allele Differences
When comparing differences of PERCs and metabolites to differences in al-
leles, transporter reactions were excluded, as stoichiometries of particular
transporters may not be known. PERCs were considered to be significantly
different between individuals if the distribution of PERCs from the 48 ensemble
models had no overlap and had a median effect size of at least a factor of 2.
Instead of using the overlap of distributions, had we used the non-parametric
Wilcoxon rank-sum test, the two-sided p value would be p = 3.23e17, which
is well below the Bonferroni adjusted p value for the number of tests done (p =
2.16e7).
To determine the association of the log2-transformed ATP/ADP ratio with
rs6051702, a linear regression model was used, accounting for sex of the
volunteer as a potential confounder. Sex was included as a potential
confounder as the erythrocyte Na-K ATPase has different kinetic properties
in males and females (Lasker et al., 1985).
Temporal Decomposition
There is a dual set of Jacobian matrices (a flux component, Jv, and a metab-
olite component, Jx) and they describe the network dynamics near the homeo-
static reference state (Jamshidi and Palsson, 2009). Using a similarity transfor-
mation (J = MLM1), the Jacobian matrix can be decomposed into its
independent dynamic components (modal matrix, M1) and their correspond-
ing eigenvalues (L), which are unique for each dual Jacobian pair (Jamshidi
and Palsson, 2008a). The modes are expressed either as fluxes or metabo-
lites, depending on which Jacobian matrix is decomposed. The eigenvalues
derived from the similarity analysis of the dual Jacobian matrices are the
same. The time constants for each mode are the negative reciprocal of the
corresponding eigenvalue. Decomposing the ensemble metabolic models,
there were 105 distinct modes, or dynamically independent groups of metab-
olites (or fluxes), in all of the personalized models. To determine the aggrega-
tion of reaction fluxes across different timescales, a previously developed
method was used (Jamshidi and Palsson, 2008b) with a correlation coefficient
threshold of 0.85.
Classification Tree
To determine potential disposition factors to RBV susceptibility, we classified
the two individuals that were responders to the drug versus the non-re-
sponders, using PERCs as the predictive variables. One-third of the ensemble
models (split evenly between responders and non-responders) were left out of
the training to be our test set. Training and validation were completed on the
remaining two-thirds of models using a 10-fold cross-validation. After building
the classifier, the predictors were used for the test set. We repeated this pro-
cess 1,000 times, removing different thirds of the models. The classification
tree was very robust, with the average misclassification percentage being
0.49% and the maximum misclassification percentage in any iteration being
1.67%. For all 1,000 iterations, the twomain predictors were PGK and adenine
transfer. The final classification tree was derived from all samples.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and three data files and can be found with this article online at
http://dx.doi.org/10.1016/j.cels.2015.10.003.
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